Search results
Results From The WOW.Com Content Network
Radioactive isotopes are used in medicine for both treatment and diagnostic scans. The most common isotope used in diagnostic scans is Technetium-99m, used in approximately 85% of all nuclear medicine diagnostic scans worldwide. It is used for diagnoses involving a large range of body parts and diseases such as cancers and neurological problems ...
This is a list of radioactive nuclides (sometimes also called isotopes), ordered by half-life from shortest to longest, in seconds, minutes, hours, days and years. Current methods make it difficult to measure half-lives between approximately 10 −19 and 10 −10 seconds.
Iodine-125 (125 I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors.
Note that medical isotopes may be not radioactive, for example deuterium (2 H) in deuterated drug. Pages in category "Medical isotopes" The following 34 pages are in this category, out of 34 total.
Often called the father of nuclear medicine, Lawrence treated a leukemia patient with radiophosphorus, which was the first time a radioactive isotope has been used to treat human patients. [4] Another pioneer in the field, Sam Seidlin, in partnership with Saul Hertz, treated a case of thyroid cancer with radioactive iodine (I-131) 1946. [5]
Iodine-123 (123 I) is a radioactive isotope of iodine used in nuclear medicine imaging, including single-photon emission computed tomography (SPECT) or SPECT/CT exams. The isotope's half-life is 13.2232 hours; [1] the decay by electron capture to tellurium-123 emits gamma radiation with a predominant energy of 159 keV (this is the gamma primarily used for imaging).
125 I is a gamma emitter with a long half-life of 59.4 days (the longest of all radioiodines used in medicine). Iodine-123 is preferred for imaging, so I-125 is used diagnostically only when the test requires a longer period to prepare the radiopharmaceutical and trace it, such as a fibrinogen scan to diagnose clotting.
This page was last edited on 16 February 2025, at 13:43 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.